Current Liabilities decreased faster than Supernus Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Supernus Pharmaceuticals Inc 's Quick Ratio to 0.62, Quick Ratio remained below Supernus Pharmaceuticals inc average.

Within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Supernus Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1567 to 2589.

Explain Quick Ratio?
How much Cash & cash equivalents SUPN�s has?
What are SUPN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SUPN/financial-strength

https://api.csimarket.com/api/v1/companies/SUPN/fundamentals

https://api.csimarket.com/api/v1/companies/SUPN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

SUPN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	95.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	16.38 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.62	Subscribe	Subscribe	Subscribe	Subscribe
SUPN's Total Ranking	# 2589	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-17.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-2.21 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 393
Healthcare Sector	# 739
Overall Market	# 2589

Quick Ratio Statistics
High	Average	Low
8.86	2.24	0.08
(Mar 31 2020)		(Mar 31 2023)

Financial Statements
Supernus Pharmaceuticals Inc 's Current Liabilities	$ 285 Millions	Visit SUPN's Balance sheet
Supernus Pharmaceuticals Inc 's Cash & cash equivalent	$ 176 Millions	Visit SUPN's Balance sheet
Source of SUPN's Sales		Visit SUPN's Sales by Geography

Cumulative Supernus Pharmaceuticals Inc 's Quick Ratio

SUPN's Quick Ratio for the trailling 12 Months

SUPN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	101.72 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	39.14 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.67	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4049	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	16.29 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.85 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to SUPN Financial Strength Comparisons >> Go to Compare SUPN Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q3 2026 to $285.40 millions, cumulative Quick Ratio decreased to 0.67 below the Supernus Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Supernus Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2986 to 4049.

Explain Quick Ratio?
How much Cash & cash equivalents SUPN�s has?
What are SUPN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 440
Healthcare Sector	# 903
Within the Market	# 4049

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.59	0.76	0.12
(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Mannkind Corporation	1.67	$ 181.525 Millions	$ 108.524 Millions
Verastem Inc	1.67	$ 172.801 Millions	$ 103.328 Millions
Agios Pharmaceuticals Inc	1.66	$ 128.549 Millions	$ 77.588 Millions
Bridgebio Pharma Inc	1.57	$ 1,538.855 Millions	$ 977.237 Millions
Arcutis Biotherapeutics Inc	1.51	$ 259.460 Millions	$ 172.357 Millions
Regeneron Pharmaceuticals Inc	1.50	$ 9,301.100 Millions	$ 6,202.100 Millions
Emergent Biosolutions Inc	1.44	$ 175.700 Millions	$ 122.000 Millions
Arbutus Biopharma Corp	1.39	$ 337.490 Millions	$ 241.933 Millions
Compass Pathways Plc	1.36	$ 443.979 Millions	$ 325.863 Millions
Sarepta Therapeutics Inc	1.34	$ 878.776 Millions	$ 656.353 Millions
Zai Lab Limited	1.32	$ 559.658 Millions	$ 424.249 Millions
Urogen Pharma Ltd	1.31	$ 96.901 Millions	$ 74.031 Millions
Ani Pharmaceuticals Inc	1.28	$ 420.758 Millions	$ 328.717 Millions
Vertex Pharmaceuticals Inc	1.26	$ 6,303.300 Millions	$ 5,000.300 Millions
Nature s Sunshine Products inc	1.22	$ 89.377 Millions	$ 73.488 Millions
Ovid Therapeutics Inc	1.16	$ 13.811 Millions	$ 11.858 Millions
Filana Therapeutics Inc	1.12	$ 46.990 Millions	$ 41.946 Millions
Phathom Pharmaceuticals Inc	1.06	$ 184.558 Millions	$ 174.902 Millions
Eton Pharmaceuticals Inc	1.03	$ 55.628 Millions	$ 54.095 Millions
Oragenics Inc	1.02	$ 2.227 Millions	$ 2.189 Millions
Geovax Labs Inc	1.01	$ 2.151 Millions	$ 2.135 Millions
Akebia Therapeutics Inc	0.98	$ 159.254 Millions	$ 162.349 Millions
Acadia Pharmaceuticals Inc	0.97	$ 322.365 Millions	$ 332.217 Millions
Alkermes Plc	0.97	$ 631.314 Millions	$ 651.933 Millions
Imunon Inc	0.95	$ 4.039 Millions	$ 4.239 Millions
Geron Corporation	0.94	$ 69.794 Millions	$ 74.248 Millions
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions

Date modified: 2026-10-30T17:00:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.